Primary Category:
Treatment Protocols
Disease Category:
Diffuse Large B-cell Lymphoma, Lymphoma, Non-Hodgkin Lymphoma
Status:
Open
Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas
NCT#03984448
A051701 accrual of patients with double expressing lymphoma (DEL) will be temporarily halted effective August 2, 2021.
A051701 accrual of patients of all ages with double hit lymphoma (DHL) is temporarily halted effective September 28, 2020.
